Key facts
- This page summarizes James N. Topper's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Apr 2024, 16:32.
James N. Topper - 25 Apr 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 25 Apr 2024
- Net transaction value
- -$26.83
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2024, 16:32:08 UTC
- Prior SEC filing
- 28 Mar 2024
- Next SEC filing
- 20 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steve Bailey, Attorney-in-Fact for James N. Topper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James N. Topper filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 29 Apr 2024.
Change
- Previous filing in this sequence was filed on 28 Mar 2024.
- Current net transaction value: -$26.83.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALPN
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $1,200
- Shares
- +1,200,000
- Change %
- +74%
- Price
- $0.001000*
- Shares after
- 2,829,366
- Date
- 25 Apr 2024
- Ownership
- By: Frazier Life Sciences VIII, L.P.
- Footnotes
- F1
ALPN
transaction
Common Stock
Sale
- Transaction value
- $1,227
- Shares
- -19
- Change %
- -0%
- Price
- $64.57
- Shares after
- 2,829,347
- Date
- 25 Apr 2024
- Ownership
- By: Frazier Life Sciences VIII, L.P.
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALPN
transaction
Derivative
Warrant (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -1,200,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Apr 2024
- Ownership
- By: Frazier Life Sciences VIII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,200,000
- Exercise price
- $0.001000
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any.
Footnote F2
On April 25, 2024, Frazier Life Sciences VIII, L.P. exercised a warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share. Frazier Life Sciences VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 19 shares of Common Stock to pay the exercise price and issuing Frazier Life Sciences VIII, L.P. the remaining 1,199,981 shares of Common Stock.
Footnote F3
The warrant had no expiration date and was exercisable immediately.